Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова, Москва; 2Кафедра психиатрии Ереванского государственного медицинского университета им. Мхитара Гераци, Армения
Список исп. литературыСкрыть список 1. BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375 (9712): 385–95. 2. Bares M, Brunovsky M, Kopecek M et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res 2007; 41 (3–4): 319–25. Epub: 2006 Aug 4. 3. Beblo T, Sinnamon G, Baune BT. Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors. Neuropsychol Rev 2011; 21 (4): 337–59. DOI: 10.1007/s11065-011-9171-0. Epub: 2011 Jun 10. 4. Cipriani A et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378 (9799): 1306–15. 5. Colom F et al. Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis. J Affect Disord 2009; 112 (1–3): 30–5. 6. Cook I, Leuchter AF, Morgan M et al. Early Changes in Prefrontal Activity Characterize Clinical Responders to Antidepressants. Neuropsychopharmacology 2002; 27 (1): 120–31. 7. Frye MA et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166 (2): 164–72. 8. Geddes JR et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375 (9712): 385–95. 9. Geddes JR et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161 (2): 217–22. 10. Kessing LV et al. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994–1999. Br J Psychiatry 2004; 185: 372–7. 11. Ketter TA et al. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011; 123 (3): 175–89. 12. Lam DH et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60 (2): 145–52. 13. Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382 (9896): 951–62. 14. Martínez-Arán A et al. Functional remediation for bipolar disorder. Clin Pract Epidemiol Ment Health 2011; 7: 112–6. 15. McIntyre RS et al. Lurasidone in bipolar depression with hypomanic symptoms. APA Annual Meeting, 2013. 16. Muralidharan K et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials. J Affect Disord 2013; 150 (2): 408–14. 17. Parikh SV et al. Psychosocial interventions for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms. Can J Psychiatry 2013; 58 (8): 482–6. 18. Popovic D et al. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012; 22 (5): 339–46. 19. Rosa AR et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand 2012; 125 (4): 335–41. 20. Sanchez-Moreno J et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009; 78 (5): 285–97. 21. Scott J et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006; 188: 313–20. 20. Torrent C et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry 2013; 170 (8): 852–9. 23. Udina M, Castellvi P, Moreno-Espana J et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128–38. 24. Valenti M et al. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord 2011; 13 (2): 145–54. 25. Vieta E. Bipolar Disorder in Clinical Practice. 3rd Ed. CMG London, 2013b. 26. Vieta E. Tertiarism in Psychiatry: The Barcelona Clinic Bipolar Disorders Programme. Rev Psiquiatr Salud Ment (Barc) 2011; 4: 1–4. 27. Vieta E et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol 2013a; 16 (8): 1719–32. 28. Vieta E et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder. J Affect Disord 2008; 109 (3): 251–63. 29. Weisler RH et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder. J Clin Psychiatry 2011; 72 (11): 1452–64. 30. Yildiz A et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011; 36 (2): 375–89.